FOR IMMEDIATE RELEASE
Media Contacts: media@hillemanlabs.org

MSD WELLCOM TRUST HILLEMAN LABORATORIES APPOINTS
GERD ZETTLMEISSL AND GORDON DOUGAN TO ITS BOARD OF DIRECTORS

Ex-CEO of Intercell to serve as Chair of the Board

New Delhi, INDIA, November 20, 2013 – The MSD Wellcome Trust Hilleman Laboratories (Hilleman Laboratories, www.hillemanlabs.org) today announced the appointment of Gerd Zettlmeissl, former Chief Executive Officer of Intercell AG and Professor Gordon Dougan FRS, Head of Pathogen Research at the Wellcome Trust Sanger Institute, to its Board of Directors.

Gerd Zettlmeissl, who will serve as the Board’s Chair, brings more than twenty years of experience in developing and commercializing vaccines gained through leadership positions at Intercell and at Chiron, one of the world’s largest biotechnology firms. Gordon Dougan, a key global advocate for increasing access to vaccines in the developing world, has extensive experience working in the vaccine industry and has pioneered work on enteric diseases. He replaces Sir Mark Walport as a Wellcome Trust representative on the Board.

“We are thrilled to welcome Gerd and Gordon to the Board,” stated Davinder Gill, CEO of Hilleman Laboratories, a joint venture founded by Merck & Co. and the Wellcome Trust to develop new and enhance existing vaccines for low-income countries. “With their combined wealth of experience in biotechnology, vaccinology and product development, we expect they will contribute significantly towards meeting our strategic research goals.”

Gerd Zettlmeissl formerly served as Chief Executive Officer at Intercell AG. He was the international Head of Industrial and Quality Operations at Chiron Vaccines, and Managing Director of Chiron Behring – a fully integrated German subsidiary of Chiron Corporation. Zettlmeissl serves on a number of Boards, including Aeras, an US based organization dedicated to the development of tuberculosis vaccines. He acts also as Chairman of GlycoVaxyn, a leading vaccine biotech company in Switzerland. He is the author of numerous scientific publications and the inventor/co-inventor of several patents in the field of biotechnology.
“I am very honored to take the chair of the MSD Wellcome Trust Hilleman Laboratories Board,” said Zettlmeissl “and to support an organization which has already made excellent contributions in its mission to become a leading player in the development of vaccine products and technologies with high impact for the developing world. We are looking forward to collaborations with other organizations and companies to further develop and manufacture our product candidates and technology platforms”.

At Wellcome Trust Sanger Institute, Professor Dougan is the Board of Management representative for the area of pathogens and Head of the Microbial Pathogenesis Group working on the genomics of host/pathogen interactions. Dougan was a former Trustee of the International Vaccine Institute in Korea and is a Fellow of the Royal Society (2012). He also is an Honorary Professor at Cambridge University. “Throughout my career as a vaccinologist, I have been most passionate about ensuring scientific innovation translates into solutions for diseases that specifically affect developing countries” said Dougan. “I am thus very pleased to join Hilleman Laboratories’ efforts.”

Both new Board members are expected to take a leadership role in developing and implementing Hilleman Laboratories’ long-term strategic direction and product portfolio. Currently the not-for-profit is conducting a feasibility study on a heat-stable rotavirus vaccine specifically designed for resource-poor countries. Researchers are examining several formulations for their potential to improve product stability, ease of use and affordability.

About MSD Wellcome Trust Hilleman Laboratories

Hilleman Laboratories is an equal joint-venture partnership formed between Merck, a global research-driven pharmaceutical company and the Wellcome Trust, a global charitable foundation dedicated to achieving extraordinary improvements in human and animal health. Headquartered in India, the research center works to develop high-impact, affordable vaccines for people in developing countries in an innovative and sustainable way.